Gamma-delta T cells to prevent leukemia relapse after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have been diagnosed with acute myeloid leukemia (AML) and had a stem cell transplant within the last 30 days (plus or minus 5 days).
- Your leukemia must have one or more high-risk signs, like not responding to treatment, having very high white blood cells, or signs of disease before transplant.
- You need to be recovered enough from past treatments, with manageable side effects.
- Your major organs (like liver, kidneys, heart, and lungs) must be working well enough based on recent tests.
- You cannot have severe graft-versus-host disease (GVHD), other cancers (unless treated), or serious heart, lung, or brain conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
Hear when a new High Risk Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.